Register or Sign in to Save this opportunity, or Send an Inquiry.
Inno-C08001 (Carvedilol CR)
Innopharmax Inc. Taiwan flag Taiwan
Abstract ID:
Inno-C08001 is indicated for the treatment of hypertension, heart failure and left ventricular dysfunction following myocardial infarction
Send an Inquiry
RE:
Participants
You
Inno-C08001 is indicated for the treatment of hypertension, heart failure and left ventricular dysfunction following myocardial infarction. The active ingredient of Inno-C08001 is poorly soluble, especially in aqueous medium, which can limit the release and absorption of the drug in the gastrointestinal tract. Its immediate release formulation is given twice daily. Inno-C08001 is designed to enhance the solubility, and as an extended-release tablet, it is intended for once-daily administration.
Type of Business Relationship Sought
License out/Co-development
FEATURED
Last Updated Mar 2019
Technology Type THERAPEUTIC
Phase of Development PHASE 3
CORPORATION

Opportunity Contact


Warning: include(js_message_scripts_n2.php) [function.include]: failed to open stream: No such file or directory in /home/pharmalicensing/public_html/detail.php on line 833

Warning: include() [function.include]: Failed opening 'js_message_scripts_n2.php' for inclusion (include_path='.:/usr/lib/php:/usr/local/lib/php') in /home/pharmalicensing/public_html/detail.php on line 833